Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide
Infection Risk Does Not Seem to Differ Among Biologics for Psoriasis
Differential risk for serious infection or respiratory tract infection, including SARS-CoV-2, not seen among biologics used to treat psoriasis
COVID-19 Vaccine Concerns ID’d in Psoriasis, Psoriatic Arthritis Patients
Patient hesitancy stems from concerns about the safety of the vaccine and whether the vaccine would aggravate their underlying condition
Papers on COVID-19 in Psoriasis, Psoriatic Arthritis Carry Risk for Bias
Risk for bias high in papers relating to patients with psoriasis and psoriatic arthritis receiving biologic therapies
Survival From COVID-19 High in Patients With Psoriasis
Risk for hospitalization increased for patients using nonbiologic systemic therapy versus biologics